KPTI closes $67.5M debt package, note exchanges & $8.75M equity; runway into Q2 2026

Karyopharm Therapeutics Inc.

$27.5M new term loan (SOFR+10.25%), $25M interest/royalty deferrals, $15M liquidity covenant relief.
Exchanged $15M 2029 notes for new 9% 2028 notes and $24.25M Oct 2025 notes for stock & warrants.
Raised $8.75M via private placement of 7.2M shares and warrants at $6.64 exercise price.
Pro forma cash ~$36M; shares outstanding ~15.9M; total debt $112.5M term loan, $15M+$103.5M convert notes.
Lenders get board observer; interest payments paid-in-kind through March 2026, cash starts June 2026.

item 1.01 item 2.02 item 2.03 item 3.02 item 5.02 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.